img

Global Adalimumab Monoclonal Antibody Biosimilar Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Adalimumab Monoclonal Antibody Biosimilar Market Insights, Forecast to 2034

Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
Global Adalimumab Monoclonal Antibody Biosimilar market is expected to reach to US$ 473 million in 2023, with a positive growth of %, compared with US$ 421 million in 2024 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Adalimumab Monoclonal Antibody Biosimilar industry is evaluated to reach US$ 958.9 million in 2034. The CAGR will be 12.5% during 2023 to 2034.
The introduction of Humira biosimilars is expected to increase competition in the market, leading to lower prices and improved access to treatment for patients. The availability of biosimilars provides an alternative option for healthcare providers and payers to choose from, potentially reducing the overall healthcare expenditure associated with biologic treatments.
Report Covers
This report presents an overview of global Adalimumab Monoclonal Antibody Biosimilar market from 2018 to 2034, aiming to help readers to get a comprehensive understanding of global Adalimumab Monoclonal Antibody Biosimilar market with multiple angles. Items like regional sales, revenue from 2018 to 2034 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2023 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2034 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Cadila Healthcare
Torrent Pharmaceuticals
Amgen
Boehringer Ingelheim
Novartis
Samsung Bioepis
Viatris
Pfizer
Fresenius Kabi
Coherus
Segment by Type
Syringe
Pen

Segment by Application


Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2034
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Adalimumab Monoclonal Antibody Biosimilar plant distribution, commercial date of Adalimumab Monoclonal Antibody Biosimilar, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2034 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2034 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2034 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2034
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2034 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2034
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2034 in China. Product sales and revenue analysis of China from 2018 to 2034
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2034 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2034
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2034 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2034.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Adalimumab Monoclonal Antibody Biosimilar introduction, etc. Adalimumab Monoclonal Antibody Biosimilar Sales, Revenue, Price and Gross Margin of each company from 2018 to 2023
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Adalimumab Monoclonal Antibody Biosimilar
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Adalimumab Monoclonal Antibody Biosimilar Product Introduction
1.2 Market by Type
1.2.1 Global Adalimumab Monoclonal Antibody Biosimilar Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Syringe
1.2.3 Pen
1.3 Market by Application
1.3.1 Global Adalimumab Monoclonal Antibody Biosimilar Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Ankylosing Spondylitis
1.3.3 Rheumatoid Arthritis
1.3.4 Crohn’s Disease
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales Estimates and Forecasts 2018-2034
2.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Region
2.2.1 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Region: 2018 VS 2024 VS 2034
2.2.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Region (2018-2023)
2.2.3 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Region (2024-2034)
2.2.4 Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Region (2018-2034)
2.3 Global Adalimumab Monoclonal Antibody Biosimilar Sales Estimates and Forecasts 2018-2034
2.4 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Region
2.4.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Region: 2018 VS 2024 VS 2034
2.4.2 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Region (2018-2023)
2.4.3 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Region (2024-2034)
2.4.4 Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Region (2018-2034)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Manufacturers
3.1.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Manufacturers (2018-2023)
3.1.2 Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Adalimumab Monoclonal Antibody Biosimilar in 2024
3.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Manufacturers
3.2.1 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Manufacturers (2018-2023)
3.2.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Adalimumab Monoclonal Antibody Biosimilar Revenue in 2024
3.3 Global Key Players of Adalimumab Monoclonal Antibody Biosimilar, Industry Ranking, 2021 VS 2024 VS 2023
3.4 Global Adalimumab Monoclonal Antibody Biosimilar Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Adalimumab Monoclonal Antibody Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Adalimumab Monoclonal Antibody Biosimilar, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Adalimumab Monoclonal Antibody Biosimilar, Product Offered and Application
3.8 Global Key Manufacturers of Adalimumab Monoclonal Antibody Biosimilar, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Type
4.1.1 Global Adalimumab Monoclonal Antibody Biosimilar Historical Sales by Type (2018-2023)
4.1.2 Global Adalimumab Monoclonal Antibody Biosimilar Forecasted Sales by Type (2024-2034)
4.1.3 Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Type (2018-2034)
4.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Type
4.2.1 Global Adalimumab Monoclonal Antibody Biosimilar Historical Revenue by Type (2018-2023)
4.2.2 Global Adalimumab Monoclonal Antibody Biosimilar Forecasted Revenue by Type (2024-2034)
4.2.3 Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Type (2018-2034)
4.3 Global Adalimumab Monoclonal Antibody Biosimilar Price by Type
4.3.1 Global Adalimumab Monoclonal Antibody Biosimilar Price by Type (2018-2023)
4.3.2 Global Adalimumab Monoclonal Antibody Biosimilar Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Application
5.1.1 Global Adalimumab Monoclonal Antibody Biosimilar Historical Sales by Application (2018-2023)
5.1.2 Global Adalimumab Monoclonal Antibody Biosimilar Forecasted Sales by Application (2024-2034)
5.1.3 Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Application (2018-2034)
5.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Application
5.2.1 Global Adalimumab Monoclonal Antibody Biosimilar Historical Revenue by Application (2018-2023)
5.2.2 Global Adalimumab Monoclonal Antibody Biosimilar Forecasted Revenue by Application (2024-2034)
5.2.3 Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Application (2018-2034)
5.3 Global Adalimumab Monoclonal Antibody Biosimilar Price by Application
5.3.1 Global Adalimumab Monoclonal Antibody Biosimilar Price by Application (2018-2023)
5.3.2 Global Adalimumab Monoclonal Antibody Biosimilar Price Forecast by Application (2024-2034)
6 US & Canada
6.1 US & Canada Adalimumab Monoclonal Antibody Biosimilar Market Size by Type
6.1.1 US & Canada Adalimumab Monoclonal Antibody Biosimilar Sales by Type (2018-2034)
6.1.2 US & Canada Adalimumab Monoclonal Antibody Biosimilar Revenue by Type (2018-2034)
6.2 US & Canada Adalimumab Monoclonal Antibody Biosimilar Market Size by Application
6.2.1 US & Canada Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2018-2034)
6.2.2 US & Canada Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2018-2034)
6.3 US & Canada Adalimumab Monoclonal Antibody Biosimilar Market Size by Country
6.3.1 US & Canada Adalimumab Monoclonal Antibody Biosimilar Revenue by Country: 2018 VS 2024 VS 2034
6.3.2 US & Canada Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2018-2034)
6.3.3 US & Canada Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2034)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Adalimumab Monoclonal Antibody Biosimilar Market Size by Type
7.1.1 Europe Adalimumab Monoclonal Antibody Biosimilar Sales by Type (2018-2034)
7.1.2 Europe Adalimumab Monoclonal Antibody Biosimilar Revenue by Type (2018-2034)
7.2 Europe Adalimumab Monoclonal Antibody Biosimilar Market Size by Application
7.2.1 Europe Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2018-2034)
7.2.2 Europe Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2018-2034)
7.3 Europe Adalimumab Monoclonal Antibody Biosimilar Market Size by Country
7.3.1 Europe Adalimumab Monoclonal Antibody Biosimilar Revenue by Country: 2018 VS 2024 VS 2034
7.3.2 Europe Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2018-2034)
7.3.3 Europe Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2034)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Adalimumab Monoclonal Antibody Biosimilar Market Size
8.1.1 China Adalimumab Monoclonal Antibody Biosimilar Sales (2018-2034)
8.1.2 China Adalimumab Monoclonal Antibody Biosimilar Revenue (2018-2034)
8.2 China Adalimumab Monoclonal Antibody Biosimilar Market Size by Application
8.2.1 China Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2018-2034)
8.2.2 China Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2018-2034)
9 Asia (excluding China)
9.1 Asia Adalimumab Monoclonal Antibody Biosimilar Market Size by Type
9.1.1 Asia Adalimumab Monoclonal Antibody Biosimilar Sales by Type (2018-2034)
9.1.2 Asia Adalimumab Monoclonal Antibody Biosimilar Revenue by Type (2018-2034)
9.2 Asia Adalimumab Monoclonal Antibody Biosimilar Market Size by Application
9.2.1 Asia Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2018-2034)
9.2.2 Asia Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2018-2034)
9.3 Asia Adalimumab Monoclonal Antibody Biosimilar Sales by Region
9.3.1 Asia Adalimumab Monoclonal Antibody Biosimilar Revenue by Region: 2018 VS 2024 VS 2034
9.3.2 Asia Adalimumab Monoclonal Antibody Biosimilar Revenue by Region (2018-2034)
9.3.3 Asia Adalimumab Monoclonal Antibody Biosimilar Sales by Region (2018-2034)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Market Size by Type
10.1.1 Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Sales by Type (2018-2034)
10.1.2 Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Revenue by Type (2018-2034)
10.2 Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Market Size by Application
10.2.1 Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2018-2034)
10.2.2 Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2018-2034)
10.3 Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Sales by Country
10.3.1 Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Revenue by Country: 2018 VS 2024 VS 2034
10.3.2 Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2034)
10.3.3 Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2018-2034)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Cadila Healthcare
11.1.1 Cadila Healthcare Company Information
11.1.2 Cadila Healthcare Overview
11.1.3 Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Cadila Healthcare Recent Developments
11.2 Torrent Pharmaceuticals
11.2.1 Torrent Pharmaceuticals Company Information
11.2.2 Torrent Pharmaceuticals Overview
11.2.3 Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Torrent Pharmaceuticals Recent Developments
11.3 Amgen
11.3.1 Amgen Company Information
11.3.2 Amgen Overview
11.3.3 Amgen Adalimumab Monoclonal Antibody Biosimilar Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 Amgen Adalimumab Monoclonal Antibody Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Amgen Recent Developments
11.4 Boehringer Ingelheim
11.4.1 Boehringer Ingelheim Company Information
11.4.2 Boehringer Ingelheim Overview
11.4.3 Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Boehringer Ingelheim Recent Developments
11.5 Novartis
11.5.1 Novartis Company Information
11.5.2 Novartis Overview
11.5.3 Novartis Adalimumab Monoclonal Antibody Biosimilar Sales, Price, Revenue and Gross Margin (2018-2023)
11.5.4 Novartis Adalimumab Monoclonal Antibody Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Novartis Recent Developments
11.6 Samsung Bioepis
11.6.1 Samsung Bioepis Company Information
11.6.2 Samsung Bioepis Overview
11.6.3 Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Sales, Price, Revenue and Gross Margin (2018-2023)
11.6.4 Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Samsung Bioepis Recent Developments
11.7 Viatris
11.7.1 Viatris Company Information
11.7.2 Viatris Overview
11.7.3 Viatris Adalimumab Monoclonal Antibody Biosimilar Sales, Price, Revenue and Gross Margin (2018-2023)
11.7.4 Viatris Adalimumab Monoclonal Antibody Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Viatris Recent Developments
11.8 Pfizer
11.8.1 Pfizer Company Information
11.8.2 Pfizer Overview
11.8.3 Pfizer Adalimumab Monoclonal Antibody Biosimilar Sales, Price, Revenue and Gross Margin (2018-2023)
11.8.4 Pfizer Adalimumab Monoclonal Antibody Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Pfizer Recent Developments
11.9 Fresenius Kabi
11.9.1 Fresenius Kabi Company Information
11.9.2 Fresenius Kabi Overview
11.9.3 Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Sales, Price, Revenue and Gross Margin (2018-2023)
11.9.4 Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Fresenius Kabi Recent Developments
11.10 Coherus
11.10.1 Coherus Company Information
11.10.2 Coherus Overview
11.10.3 Coherus Adalimumab Monoclonal Antibody Biosimilar Sales, Price, Revenue and Gross Margin (2018-2023)
11.10.4 Coherus Adalimumab Monoclonal Antibody Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Coherus Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Adalimumab Monoclonal Antibody Biosimilar Industry Chain Analysis
12.2 Adalimumab Monoclonal Antibody Biosimilar Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Adalimumab Monoclonal Antibody Biosimilar Production Mode & Process
12.4 Adalimumab Monoclonal Antibody Biosimilar Sales and Marketing
12.4.1 Adalimumab Monoclonal Antibody Biosimilar Sales Channels
12.4.2 Adalimumab Monoclonal Antibody Biosimilar Distributors
12.5 Adalimumab Monoclonal Antibody Biosimilar Customers
13 Market Dynamics
13.1 Adalimumab Monoclonal Antibody Biosimilar Industry Trends
13.2 Adalimumab Monoclonal Antibody Biosimilar Market Drivers
13.3 Adalimumab Monoclonal Antibody Biosimilar Market Challenges
13.4 Adalimumab Monoclonal Antibody Biosimilar Market Restraints
14 Key Findings in The Global Adalimumab Monoclonal Antibody Biosimilar Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Adalimumab Monoclonal Antibody Biosimilar Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Syringe
Table 3. Major Manufacturers of Pen
Table 4. Global Adalimumab Monoclonal Antibody Biosimilar Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 5. Global Adalimumab Monoclonal Antibody Biosimilar Revenue Grow Rate (CAGR) by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 6. Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Region (2018-2023) & (US$ Million)
Table 7. Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Region (2024-2034) & (US$ Million)
Table 8. Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Region (2018-2023)
Table 9. Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Region (2024-2034)
Table 10. Global Adalimumab Monoclonal Antibody Biosimilar Sales Grow Rate (CAGR) by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 11. Global Adalimumab Monoclonal Antibody Biosimilar Sales by Region (2018-2023) & (K Units)
Table 12. Global Adalimumab Monoclonal Antibody Biosimilar Sales by Region (2024-2034) & (K Units)
Table 13. Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Region (2018-2023)
Table 14. Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Region (2024-2034)
Table 15. Global Adalimumab Monoclonal Antibody Biosimilar Sales by Manufacturers (2018-2023) & (K Units)
Table 16. Global Adalimumab Monoclonal Antibody Biosimilar Sales Share by Manufacturers (2018-2023)
Table 17. Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 18. Global Adalimumab Monoclonal Antibody Biosimilar Revenue Share by Manufacturers (2018-2023)
Table 19. Global Key Players of Adalimumab Monoclonal Antibody Biosimilar, Industry Ranking, 2021 VS 2024 VS 2023
Table 20. Adalimumab Monoclonal Antibody Biosimilar Price by Manufacturers 2018-2023 (US$/Unit)
Table 21. Global Adalimumab Monoclonal Antibody Biosimilar Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Adalimumab Monoclonal Antibody Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adalimumab Monoclonal Antibody Biosimilar as of 2024)
Table 23. Global Key Manufacturers of Adalimumab Monoclonal Antibody Biosimilar, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Adalimumab Monoclonal Antibody Biosimilar, Product Offered and Application
Table 25. Global Key Manufacturers of Adalimumab Monoclonal Antibody Biosimilar, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Adalimumab Monoclonal Antibody Biosimilar Sales by Type (2018-2023) & (K Units)
Table 28. Global Adalimumab Monoclonal Antibody Biosimilar Sales by Type (2024-2034) & (K Units)
Table 29. Global Adalimumab Monoclonal Antibody Biosimilar Sales Share by Type (2018-2023)
Table 30. Global Adalimumab Monoclonal Antibody Biosimilar Sales Share by Type (2024-2034)
Table 31. Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Type (2018-2023) & (US$ Million)
Table 32. Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Adalimumab Monoclonal Antibody Biosimilar Revenue Share by Type (2018-2023)
Table 34. Global Adalimumab Monoclonal Antibody Biosimilar Revenue Share by Type (2024-2034)
Table 35. Adalimumab Monoclonal Antibody Biosimilar Price by Type (2018-2023) & (US$/Unit)
Table 36. Global Adalimumab Monoclonal Antibody Biosimilar Price Forecast by Type (2024-2034) & (US$/Unit)
Table 37. Global Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2018-2023) & (K Units)
Table 38. Global Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2024-2034) & (K Units)
Table 39. Global Adalimumab Monoclonal Antibody Biosimilar Sales Share by Application (2018-2023)
Table 40. Global Adalimumab Monoclonal Antibody Biosimilar Sales Share by Application (2024-2034)
Table 41. Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2018-2023) & (US$ Million)
Table 42. Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Adalimumab Monoclonal Antibody Biosimilar Revenue Share by Application (2018-2023)
Table 44. Global Adalimumab Monoclonal Antibody Biosimilar Revenue Share by Application (2024-2034)
Table 45. Adalimumab Monoclonal Antibody Biosimilar Price by Application (2018-2023) & (US$/Unit)
Table 46. Global Adalimumab Monoclonal Antibody Biosimilar Price Forecast by Application (2024-2034) & (US$/Unit)
Table 47. US & Canada Adalimumab Monoclonal Antibody Biosimilar Sales by Type (2018-2023) & (K Units)
Table 48. US & Canada Adalimumab Monoclonal Antibody Biosimilar Sales by Type (2024-2034) & (K Units)
Table 49. US & Canada Adalimumab Monoclonal Antibody Biosimilar Revenue by Type (2018-2023) & (US$ Million)
Table 50. US & Canada Adalimumab Monoclonal Antibody Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 51. US & Canada Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2018-2023) & (K Units)
Table 52. US & Canada Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2024-2034) & (K Units)
Table 53. US & Canada Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2018-2023) & (US$ Million)
Table 54. US & Canada Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 55. US & Canada Adalimumab Monoclonal Antibody Biosimilar Revenue Grow Rate (CAGR) by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 56. US & Canada Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2023) & (US$ Million)
Table 57. US & Canada Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2024-2034) & (US$ Million)
Table 58. US & Canada Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2018-2023) & (K Units)
Table 59. US & Canada Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2024-2034) & (K Units)
Table 60. Europe Adalimumab Monoclonal Antibody Biosimilar Sales by Type (2018-2023) & (K Units)
Table 61. Europe Adalimumab Monoclonal Antibody Biosimilar Sales by Type (2024-2034) & (K Units)
Table 62. Europe Adalimumab Monoclonal Antibody Biosimilar Revenue by Type (2018-2023) & (US$ Million)
Table 63. Europe Adalimumab Monoclonal Antibody Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 64. Europe Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2018-2023) & (K Units)
Table 65. Europe Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2024-2034) & (K Units)
Table 66. Europe Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2018-2023) & (US$ Million)
Table 67. Europe Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 68. Europe Adalimumab Monoclonal Antibody Biosimilar Revenue Grow Rate (CAGR) by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 69. Europe Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2023) & (US$ Million)
Table 70. Europe Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2024-2034) & (US$ Million)
Table 71. Europe Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2018-2023) & (K Units)
Table 72. Europe Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2024-2034) & (K Units)
Table 73. China Adalimumab Monoclonal Antibody Biosimilar Sales by Type (2018-2023) & (K Units)
Table 74. China Adalimumab Monoclonal Antibody Biosimilar Sales by Type (2024-2034) & (K Units)
Table 75. China Adalimumab Monoclonal Antibody Biosimilar Revenue by Type (2018-2023) & (US$ Million)
Table 76. China Adalimumab Monoclonal Antibody Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 77. China Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2018-2023) & (K Units)
Table 78. China Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2024-2034) & (K Units)
Table 79. China Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2018-2023) & (US$ Million)
Table 80. China Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 81. Asia Adalimumab Monoclonal Antibody Biosimilar Sales by Type (2018-2023) & (K Units)
Table 82. Asia Adalimumab Monoclonal Antibody Biosimilar Sales by Type (2024-2034) & (K Units)
Table 83. Asia Adalimumab Monoclonal Antibody Biosimilar Revenue by Type (2018-2023) & (US$ Million)
Table 84. Asia Adalimumab Monoclonal Antibody Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 85. Asia Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2018-2023) & (K Units)
Table 86. Asia Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2024-2034) & (K Units)
Table 87. Asia Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2018-2023) & (US$ Million)
Table 88. Asia Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 89. Asia Adalimumab Monoclonal Antibody Biosimilar Revenue Grow Rate (CAGR) by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 90. Asia Adalimumab Monoclonal Antibody Biosimilar Revenue by Region (2018-2023) & (US$ Million)
Table 91. Asia Adalimumab Monoclonal Antibody Biosimilar Revenue by Region (2024-2034) & (US$ Million)
Table 92. Asia Adalimumab Monoclonal Antibody Biosimilar Sales by Region (2018-2023) & (K Units)
Table 93. Asia Adalimumab Monoclonal Antibody Biosimilar Sales by Region (2024-2034) & (K Units)
Table 94. Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Sales by Type (2018-2023) & (K Units)
Table 95. Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Sales by Type (2024-2034) & (K Units)
Table 96. Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Revenue by Type (2018-2023) & (US$ Million)
Table 97. Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 98. Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2018-2023) & (K Units)
Table 99. Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2024-2034) & (K Units)
Table 100. Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2018-2023) & (US$ Million)
Table 101. Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 102. Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Revenue Grow Rate (CAGR) by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 103. Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2023) & (US$ Million)
Table 104. Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2024-2034) & (US$ Million)
Table 105. Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2018-2023) & (K Units)
Table 106. Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2024-2034) & (K Units)
Table 107. Cadila Healthcare Company Information
Table 108. Cadila Healthcare Description and Major Businesses
Table 109. Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 110. Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Cadila Healthcare Recent Developments
Table 112. Torrent Pharmaceuticals Company Information
Table 113. Torrent Pharmaceuticals Description and Major Businesses
Table 114. Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 115. Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Torrent Pharmaceuticals Recent Developments
Table 117. Amgen Company Information
Table 118. Amgen Description and Major Businesses
Table 119. Amgen Adalimumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 120. Amgen Adalimumab Monoclonal Antibody Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Amgen Recent Developments
Table 122. Boehringer Ingelheim Company Information
Table 123. Boehringer Ingelheim Description and Major Businesses
Table 124. Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 125. Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Boehringer Ingelheim Recent Developments
Table 127. Novartis Company Information
Table 128. Novartis Description and Major Businesses
Table 129. Novartis Adalimumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 130. Novartis Adalimumab Monoclonal Antibody Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Novartis Recent Developments
Table 132. Samsung Bioepis Company Information
Table 133. Samsung Bioepis Description and Major Businesses
Table 134. Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 135. Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Samsung Bioepis Recent Developments
Table 137. Viatris Company Information
Table 138. Viatris Description and Major Businesses
Table 139. Viatris Adalimumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 140. Viatris Adalimumab Monoclonal Antibody Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Viatris Recent Developments
Table 142. Pfizer Company Information
Table 143. Pfizer Description and Major Businesses
Table 144. Pfizer Adalimumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 145. Pfizer Adalimumab Monoclonal Antibody Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Pfizer Recent Developments
Table 147. Fresenius Kabi Company Information
Table 148. Fresenius Kabi Description and Major Businesses
Table 149. Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 150. Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Fresenius Kabi Recent Developments
Table 152. Coherus Company Information
Table 153. Coherus Description and Major Businesses
Table 154. Coherus Adalimumab Monoclonal Antibody Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 155. Coherus Adalimumab Monoclonal Antibody Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Coherus Recent Developments
Table 157. Key Raw Materials Lists
Table 158. Raw Materials Key Suppliers Lists
Table 159. Adalimumab Monoclonal Antibody Biosimilar Distributors List
Table 160. Adalimumab Monoclonal Antibody Biosimilar Customers List
Table 161. Adalimumab Monoclonal Antibody Biosimilar Market Trends
Table 162. Adalimumab Monoclonal Antibody Biosimilar Market Drivers
Table 163. Adalimumab Monoclonal Antibody Biosimilar Market Challenges
Table 164. Adalimumab Monoclonal Antibody Biosimilar Market Restraints
Table 165. Research Programs/Design for This Report
Table 166. Key Data Information from Secondary Sources
Table 167. Key Data Information from Primary Sources
List of Figures
Figure 1. Adalimumab Monoclonal Antibody Biosimilar Product Picture
Figure 2. Global Adalimumab Monoclonal Antibody Biosimilar Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Adalimumab Monoclonal Antibody Biosimilar Market Share by Type in 2024 & 2034
Figure 4. Syringe Product Picture
Figure 5. Pen Product Picture
Figure 6. Global Adalimumab Monoclonal Antibody Biosimilar Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 7. Global Adalimumab Monoclonal Antibody Biosimilar Market Share by Application in 2024 & 2034
Figure 8. Ankylosing Spondylitis
Figure 9. Rheumatoid Arthritis
Figure 10. Crohn’s Disease
Figure 11. Other
Figure 12. Adalimumab Monoclonal Antibody Biosimilar Report Years Considered
Figure 13. Global Adalimumab Monoclonal Antibody Biosimilar Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 14. Global Adalimumab Monoclonal Antibody Biosimilar Revenue 2018-2034 (US$ Million)
Figure 15. Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 16. Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Region (2018-2034)
Figure 17. Global Adalimumab Monoclonal Antibody Biosimilar Sales 2018-2034 ((K Units)
Figure 18. Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Region (2018-2034)
Figure 19. US & Canada Adalimumab Monoclonal Antibody Biosimilar Sales YoY (2018-2034) & (K Units)
Figure 20. US & Canada Adalimumab Monoclonal Antibody Biosimilar Revenue YoY (2018-2034) & (US$ Million)
Figure 21. Europe Adalimumab Monoclonal Antibody Biosimilar Sales YoY (2018-2034) & (K Units)
Figure 22. Europe Adalimumab Monoclonal Antibody Biosimilar Revenue YoY (2018-2034) & (US$ Million)
Figure 23. China Adalimumab Monoclonal Antibody Biosimilar Sales YoY (2018-2034) & (K Units)
Figure 24. China Adalimumab Monoclonal Antibody Biosimilar Revenue YoY (2018-2034) & (US$ Million)
Figure 25. Asia (excluding China) Adalimumab Monoclonal Antibody Biosimilar Sales YoY (2018-2034) & (K Units)
Figure 26. Asia (excluding China) Adalimumab Monoclonal Antibody Biosimilar Revenue YoY (2018-2034) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Sales YoY (2018-2034) & (K Units)
Figure 28. Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Revenue YoY (2018-2034) & (US$ Million)
Figure 29. The Adalimumab Monoclonal Antibody Biosimilar Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2024
Figure 30. The Top 5 and 10 Largest Manufacturers of Adalimumab Monoclonal Antibody Biosimilar in the World: Market Share by Adalimumab Monoclonal Antibody Biosimilar Revenue in 2024
Figure 31. Global Adalimumab Monoclonal Antibody Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 32. Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Type (2018-2034)
Figure 33. Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Type (2018-2034)
Figure 34. Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Application (2018-2034)
Figure 35. Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Application (2018-2034)
Figure 36. US & Canada Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Type (2018-2034)
Figure 37. US & Canada Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Type (2018-2034)
Figure 38. US & Canada Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Application (2018-2034)
Figure 39. US & Canada Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Application (2018-2034)
Figure 40. US & Canada Adalimumab Monoclonal Antibody Biosimilar Revenue Share by Country (2018-2034)
Figure 41. US & Canada Adalimumab Monoclonal Antibody Biosimilar Sales Share by Country (2018-2034)
Figure 42. U.S. Adalimumab Monoclonal Antibody Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 43. Canada Adalimumab Monoclonal Antibody Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 44. Europe Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Type (2018-2034)
Figure 45. Europe Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Type (2018-2034)
Figure 46. Europe Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Application (2018-2034)
Figure 47. Europe Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Application (2018-2034)
Figure 48. Europe Adalimumab Monoclonal Antibody Biosimilar Revenue Share by Country (2018-2034)
Figure 49. Europe Adalimumab Monoclonal Antibody Biosimilar Sales Share by Country (2018-2034)
Figure 50. Germany Adalimumab Monoclonal Antibody Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 51. France Adalimumab Monoclonal Antibody Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 52. U.K. Adalimumab Monoclonal Antibody Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 53. Italy Adalimumab Monoclonal Antibody Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 54. Russia Adalimumab Monoclonal Antibody Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 55. China Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Type (2018-2034)
Figure 56. China Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Type (2018-2034)
Figure 57. China Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Application (2018-2034)
Figure 58. China Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Application (2018-2034)
Figure 59. Asia Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Type (2018-2034)
Figure 60. Asia Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Type (2018-2034)
Figure 61. Asia Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Application (2018-2034)
Figure 62. Asia Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Application (2018-2034)
Figure 63. Asia Adalimumab Monoclonal Antibody Biosimilar Revenue Share by Region (2018-2034)
Figure 64. Asia Adalimumab Monoclonal Antibody Biosimilar Sales Share by Region (2018-2034)
Figure 65. Japan Adalimumab Monoclonal Antibody Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 66. South Korea Adalimumab Monoclonal Antibody Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 67. China Taiwan Adalimumab Monoclonal Antibody Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 68. Southeast Asia Adalimumab Monoclonal Antibody Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 69. India Adalimumab Monoclonal Antibody Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 70. Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Type (2018-2034)
Figure 71. Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Type (2018-2034)
Figure 72. Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Application (2018-2034)
Figure 73. Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Application (2018-2034)
Figure 74. Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Revenue Share by Country (2018-2034)
Figure 75. Middle East, Africa and Latin America Adalimumab Monoclonal Antibody Biosimilar Sales Share by Country (2018-2034)
Figure 76. Brazil Adalimumab Monoclonal Antibody Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 77. Mexico Adalimumab Monoclonal Antibody Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 78. Turkey Adalimumab Monoclonal Antibody Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 79. Israel Adalimumab Monoclonal Antibody Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 80. GCC Countries Adalimumab Monoclonal Antibody Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 81. Adalimumab Monoclonal Antibody Biosimilar Value Chain
Figure 82. Adalimumab Monoclonal Antibody Biosimilar Production Process
Figure 83. Channels of Distribution
Figure 84. Distributors Profiles
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries